| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/13/2005 | US20050009874 Tetrahydropyridin or piperidino heterocyclic derivatives |
| 01/13/2005 | US20050009850 Quinazoline compounds with therapeutic use |
| 01/13/2005 | US20050009838 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 01/13/2005 | US20050009816 Potassium channel modulators |
| 01/13/2005 | US20050009792 (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses |
| 01/13/2005 | US20050009780 Use of oversulfated polysaccharides as inhibitors of hiv |
| 01/13/2005 | US20050009755 (74)(3S)-3-amino-1-(1-benzyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-4-yl)-5-methyl-2-heptanone for example; cysteine protease inhibitors; treating bone resorption diseases such as osteoporosis |
| 01/13/2005 | US20050009751 Pentapeptide compounds and uses related thereto |
| 01/13/2005 | US20050009202 Methods and compositions for use in the diagnosis and treatment of chronic immune disease |
| 01/13/2005 | US20050009145 Mammalian receptor proteins; related reagents and methods |
| 01/13/2005 | US20050009144 Transgenic cell comprising nucleotide sequences coding endostatins for use as tool in identifying modulators for treatment and prevention of cell proliferative and angiogenesis-related disorders |
| 01/13/2005 | US20050009025 A soluble T cell receptor for use as diagnostic indicator of infection and autoimmune diseases |
| 01/13/2005 | US20050008655 Useful as barrier applied to skin; chemical and radiation resistance; skin disorders; autoimmune diseases; antitumor agents; topical applying |
| 01/13/2005 | US20050008644 Potentiation of the immune response |
| 01/13/2005 | US20050008640 Method of treating transplant rejection |
| 01/13/2005 | US20050008637 Cancer therapy; antiinflammatory agents; autoimmune disease |
| 01/13/2005 | US20050008636 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 01/13/2005 | US20050008634 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| 01/13/2005 | US20050008581 Methods and compositions that enhance bioavailability of coenzyme-Q10 |
| 01/13/2005 | DE10327518A1 Synthetische Peptidkombinationen und Verfahren zu deren Herstellung Synthetic peptide combinations and methods for their preparation |
| 01/13/2005 | CA2530480A1 Conjugated complement cascade inhibitors |
| 01/13/2005 | CA2529244A1 Rapamycin resistant t cells and therapeutic uses thereof |
| 01/13/2005 | CA2529057A1 Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
| 01/12/2005 | EP1496121A2 Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
| 01/12/2005 | EP1496109A1 Process for producing cytotoxic lymphocyte |
| 01/12/2005 | EP1496059A1 Fused bicyclic pyrimidine derivatives |
| 01/12/2005 | EP1495767A1 Immunoadjuvant |
| 01/12/2005 | EP1495757A1 Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative |
| 01/12/2005 | EP1495756A1 Severe sepsis preventive therapeutic agent |
| 01/12/2005 | EP1495322A2 Heteroclitic analogs and related methods |
| 01/12/2005 | EP1495117A2 Human deubiquitinating protease gene on chromosome 7 and its murine ortholog |
| 01/12/2005 | EP1495115A2 Nucleic acid sequence and protein in addition to polypeptides coding for mannitol-dehydrogenases or parts thereof and the production and use thereof in diagnosis and therapy |
| 01/12/2005 | EP1495111A2 Novel methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells |
| 01/12/2005 | EP1495110A1 Recombinant spores |
| 01/12/2005 | EP1495052A1 Modified factor viii |
| 01/12/2005 | EP1495031A1 Labeled oxazinocarbazoles as diagnostic agents |
| 01/12/2005 | EP1495022A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity |
| 01/12/2005 | EP1495020A1 N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases |
| 01/12/2005 | EP1495017A2 Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators |
| 01/12/2005 | EP1495016A2 Heterocyclic compounds and their use as modulators of p38 map kinase |
| 01/12/2005 | EP1495009A2 Cyanamides useful as reversible inhibitors of cysteine proteases |
| 01/12/2005 | EP1495005A1 Pyrazole compounds as anti-inflammatory and analgesic agents |
| 01/12/2005 | EP1495003A1 Fredericamycin derivatives |
| 01/12/2005 | EP1494992A2 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 01/12/2005 | EP1494752A1 Method of treating biological materials with translating electrical fields and electrode polarity reversal |
| 01/12/2005 | EP1494722A1 Treatment methods for eotaxin mediated inflammatory conditions |
| 01/12/2005 | EP1494710A2 Diabetes-related immunoglobulin derived proteins, compostions, methods and uses |
| 01/12/2005 | EP1494703A1 Chemokines mutants having improved oral bioavailability |
| 01/12/2005 | EP1494701A2 Immunosuppressant compounds, methods and uses related thereto |
| 01/12/2005 | EP1494692A1 Topical pharmaceutical compositions comprising proanthocyanidins for the treatment of dermatitis |
| 01/12/2005 | EP1494687A2 Immunomodulatory polymeric antigens for treating inflammatory pathogies |
| 01/12/2005 | EP1494671A1 1-(4-piperidinyl)benzimidazolones as histamine h3 antagonists |
| 01/12/2005 | EP1494669A1 Medicament for preventing and/or treating chronic rejection |
| 01/12/2005 | EP1494667A1 Imidazole compounds as anti-inflammatory and analgesic agents |
| 01/12/2005 | EP1494665A1 Use of statins and other immunomodulatory agents in the treatment of autoimmune disease |
| 01/12/2005 | EP1494661A1 Ptx3 gene expression suppressing method |
| 01/12/2005 | EP1494542A1 Composition for modulating a physiological reaction or inducing an immune response |
| 01/12/2005 | EP1459760A9 Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof |
| 01/12/2005 | EP1307216A4 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 01/12/2005 | EP1185241B1 Compositions containing avenanthramides from oat extract |
| 01/12/2005 | EP1183254B1 Substituted bicyclic heteroaryl compounds as integrin antagonists |
| 01/12/2005 | EP1105370B9 Novel aryl sulphonamides and analogues |
| 01/12/2005 | EP1089713B1 Temperature-sensitive liposomal formulation |
| 01/12/2005 | EP1063987A4 Dietary control of arachidonic acid metabolism |
| 01/12/2005 | EP1030851B1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 01/12/2005 | EP0958823B1 Azelastine hydrochloride-containing percutaneous preparation having good percutaneous absorbability and reduced skin irritation |
| 01/12/2005 | EP0750513B1 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
| 01/12/2005 | CN1564826A Human G-protein chemokine receptor (CCR5) HDGNR10 |
| 01/12/2005 | CN1564821A 5-methoxy-8-aryl-[1, 2, 4]triazolo[1, 5-a]pyridine derivatives as adenosine receptor antagonists |
| 01/12/2005 | CN1564816A Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 01/12/2005 | CN1564696A Compositions for and methods of treating and preventing sirs/sepsis |
| 01/12/2005 | CN1564687A Use of phosphodiesterase IV inhibitors |
| 01/12/2005 | CN1564686A 8-amino- [1, 2, 4]triazolo [1, 5-a]pyridine-6-carboxylic acid amide |
| 01/12/2005 | CN1564685A Pyrrolidinone derivatives |
| 01/12/2005 | CN1564684A Pharmaceutical compositions |
| 01/12/2005 | CN1562362A Mosaic type DNA vaccine in use for preventing tuberculosis and immunological therapy |
| 01/12/2005 | CN1562343A Compound preparation of Azithromycin and Pidotimod |
| 01/12/2005 | CN1562334A Method of supercritical CO2 for extracting effective constituent from whole spores of ganoderma lucidum |
| 01/12/2005 | CN1562283A Medicinal use of spanish moss of Chinese traditional medicine |
| 01/12/2005 | CN1562278A Application of cocoa extract in preparing medication of anti irritability and anti inflammation, foodstuff and cosmetic |
| 01/12/2005 | CN1562136A Compound super fine dendrobium candidum soft capsule and its preparing method |
| 01/12/2005 | CN1562083A Method for preparing musk freeze-dried powder injection |
| 01/12/2005 | CN1561994A Medicinal compositon containing artemisine extract for treating rheumatoid arthritis and immunologic disease |
| 01/12/2005 | CN1561990A Treatment of immune diseases |
| 01/12/2005 | CN1184320C Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment |
| 01/12/2005 | CN1184315C Death domain containing receptor 5 |
| 01/12/2005 | CN1184314C Gene engineering preparation method of Chinese human being costimulation signal inhibition factor |
| 01/12/2005 | CN1184204C Piperidine compounds for use as CCR-3 inhibitors |
| 01/12/2005 | CN1183960C Use of bifidobacterium cell wall and bifidobacterium cell wall protein in pharmacy |
| 01/11/2005 | US6841678 Hofmann degradation of amide to amine |
| 01/11/2005 | US6841674 N-heterocyclic derivatives as NOS inhibitors |
| 01/11/2005 | US6841673 Enzyme inhibitors; antiinflammatory agents; rheumatic diseases; antidiabetic agents |
| 01/11/2005 | US6841571 Compounds useful as reversible inhibitors of cysteine proteases |
| 01/11/2005 | US6841567 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 01/11/2005 | US6841564 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/11/2005 | US6841550 Benzoxazine and benzothiazine derivatives and their use in medicines |
| 01/11/2005 | US6841543 Contacting a human immune cell with a sufficient amount of a pharmaceutical composition consisting essentially of non-crosslinked, monovalent Lewisx antigen consisting of LNFP-III lacto-N-fucopentaose III |
| 01/11/2005 | US6841530 Semi-synthetic studies toward didemnin analogues |
| 01/11/2005 | CA2269128C Piperazino derivatives as neurokinin antagonists |
| 01/11/2005 | CA2267670C Method for preparing human stem cell factor polypeptide |